PROFOOT, INC. v. BAYER HEALTHCARE LLC et al
Filing
68
OPINION & ORDER denying 42 Plaintiff's Motion for Preliminary Injunction. Signed by Judge Anne E. Thompson on 6/14/2012. (eaj)
NOT FOR PUBLICATION
UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY
PROFOOT, INC.,
Plaintiff,
Civ. No. 11-7079
v.
OPINION
MSD CONSUMER CARE, INC.,
Defendant.
THOMPSON, U.S.D.J.
This matter has come before the Court on Plaintiff ProFoot, Inc.’s (“ProFoot”) Motion
for a Preliminary Injunction [42]. Defendant MSD Consumer Care, Inc. (“MSD”) opposes this
motion [50]. An evidentiary hearing was held in this matter on May 17, 2012, at which time the
parties gave oral argument, presented witness testimony, and submitted documentary evidence.
After considering all of the submissions of the parties the Court has reached a determination
pursuant to Federal Rule of Civil Procedure 78(a). For the following reasons, ProFoot’s motion
will be denied.
I.
BACKGROUND
This dispute arises out of the marketing strategies adopted by two competing companies
in the foot-care products market. ProFoot is the maker of numerous foot-care products that use
registered trademarks consisting of different iterations of the word “ProFoot.” See, e.g.,
(Feldman Aff., Ex. E). ProFoot, however, does not sell products under a “Pro” brand, separately
advertise their products using only the word “Pro,” or own any “Pro” trademark registrations.
1
(Tr. 63:15–18, 64:11–17, 99:13–24).1 MSD, the maker of Dr. Scholl’s foot care products, has
sold a line of orthotic shoe insoles under the brand name “Dr. Scholl’s Pain Relief Orthotics”
since 2006. (Howard Decl. ¶ 13). During the summer of 2011, ProFoot became aware that MSD
was considering marketing its line of Pain Relief Orthotics under the acronym “P.R.O.” (Tr.
47:18–48:7). Soon after, in either late August or early September of 2011, ProFoot noticed
MSD’s Pain Relief Orthotic line of foot care products in the market using the designation
“P.R.O.” (Id. 49:18–24). This suit followed. Plaintiff now seeks to preliminarily enjoin MSD
from using the P.R.O. acronym on the Dr. Scholl’s Pain Relief Orthotic product packaging and
from advertising their Pain Relief Orthotic products by using the word “pro” or the P.R.O.
acronym.
II.
LEGAL STANDARD
The Lanham Act, 15 U.S.C. § 1051, et seq., empowers a federal district court to issue an
injunction in order to prevent a trademark violation in accordance with “the principles of equity
and upon such terms as the court may deem reasonable.” 15 U.S.C. § 1116(a). Prior to a trial on
the merits, a preliminary injunction is warranted where it is necessary to preserve the status quo
before resolution of the case. Univ. of Tex. v. Camenisch, 451 U.S. 390, 395 (1981).
Preliminary relief, however, is “an extraordinary remedy” that should be granted “only in limited
circumstances.” AT&T Co. v. Winback & Conserve Program, Inc., 42 F.3d 1421, 1427 (3d Cir.
1994) (internal quotation omitted). The party seeking a preliminary injunction has the burden of
showing: “(1) a likelihood of success on the merits; (2) that it will suffer irreparable harm if the
injunction is denied; (3) that granting preliminary relief will not result in even greater harm to the
nonmoving party; and (4) that the public interest favors such relief.” Kos Pharm., Inc. v. Andrx
1
Plaintiff did at one point sell other products using the surname “Pro” but has not sold any such products since
2006. (Tr. 99:10–24). Trademarks that are not used for three years are presumptively considered to be abandoned.
See 15 U.S.C. § 1127.
2
Corp., 369 F.3d 700, 708 (3d Cir. 2004) (citing Allegheny Energy, Inc. v. DQE, Inc., 171 F.3d
153, 158 (3d 1999)).
III.
LIKELIHOOD OF SUCCESS ON THE MERITS
“The law of trademark protects trademark owners in the exclusive use of their marks
when use by another would be likely to cause confusion.” Interpace Corp. v. Lapp, Inc., 721
F.2d 460, 462 (3d Cir. 1983) [hereinafter “Lapp”]. A successful claim under the Lanham Act for
trademark infringement requires a plaintiff to show (1) that it owns the mark at issue, (2) that its
mark is both valid and legally protectable, and (3) that the defendant’s use of the mark to identify
its products is likely to cause confusion concerning the origin of those products. See, e.g.,
Commerce Nat’l Ins. Servs., Inc. v. Commerce Ins. Agency, Inc., 214 F.3d 432, 437 (3d Cir.
2000).
The parties in this case do not dispute that ProFoot has ownership over a valid and legally
protectable mark. MSD notes, however, that ProFoot does not have ownership over any
trademarks using only the word “pro” and argues that this case must be looked at through this
lens—i.e., the Court must keep in mind that the trademark at issue consists of the word
“ProFoot” and not simply “pro.” The main dispute amongst the parties under the first prong of a
preliminary injunction analysis is whether MSD’s use of the P.R.O. acronym for its Pain Relief
Orthotic line of foot-care products is likely to cause confusion as to the origin of those products
or as to any of ProFoot’s products. “Likelihood of confusion exists when consumers viewing the
mark would probably assume that the product or service it represents is associated with the
source of a different product or service identified by a similar mark.” Scott Paper Co. v. Scott’s
Liquid Gold, Inc., 589 F.2d 1225, 1229 (3d Cir. 1978) (citing James Burrough, Ltd. v. Sign of
Beefeater, Inc., 540 F.2d 266, 275 (3d Cir. 1976)).
3
In cases such as this, where two products are directly competing in the market, a court
“need rarely look beyond the mark itself” in determining whether there is a likelihood of
confusion. Lapp, 721 F.2d at 462. Nevertheless, a number of factors have been identified by the
courts in determining whether two marks are likely to be confused with one another. These
factors, commonly referred to as the Lapp factors, include the following:
(1) the degree of similarity between the owner’s mark and the alleged infringing
mark;
(2) the strength of the owner’s mark;
(3) the price of the goods and other factors indicative of the care and attention
expected of consumers when making a purchase;
(4) the length of time the defendant has used the mark without evidence of actual
confusion arising;
(5) the intent of the defendant in adopting the mark;
(6) the evidence of actual confusion;
(7) whether the goods, though not competing, are marketed through the same
channels of trade and advertised through the same media;
(8) the extent to which the targets of the parties’ sales efforts are the same;
(9) the relationship of the goods in the minds of consumers because of the
similarity of function;
(10) other facts suggesting that the consuming public might expect the prior
owner to manufacture a product in the defendant’s market, or that he is likely to
expand into that market.
Id. at 463 (citing Scott Paper Co., 589 F.2d at 1229); see also A&H Sportswear, Inc. v. Victoria’s
Secret Stores, Inc., 237 F.3d 198, 212–13 (3d Cir. 2000) (applying these factors to directly
competing goods). Despite this list of factors, “[a] district court should not be foreclosed from
using any factors that it deems helpful in analyzing whether a likelihood of confusion exists
between given products.” A&H Sportswear, Inc., 237 F.3d at 212. These factors “are meant to
be tools, not hurdles.” Id. at 214. A court need not consider each factor in every case and can
look to additional facts relevant to the specific circumstances of a case. Id. at 214–15. Similarly,
“the different factors may properly be accorded different weights depending on the particular
factual setting.” Id. at 215.
4
In this case, Plaintiff alleges both direct and reverse confusion. A direct confusion claim
exists when the junior user (here, MSD) purportedly attempts to free-ride on the “reputation and
good will of the senior user by adopting a similar or identical mark.” Id. at 228. By contrast,
“[t]he harm flowing from reverse confusion is that the public comes to assume the senior user’s
products are really the junior user’s or that the former has become somehow connected to the
later.” Id. (citations omitted). Under either theory, the ultimate question is the same: “whether
[or not] there is a likelihood of consumer confusion as to the source or sponsorship of a product.”
Id. at 229. The Lapp factors are used in analyzing both direct and reverse confusion claims. Id.
After reviewing the evidence submitted by the parties the Court has determined that
Plaintiff has not met its burden in establishing that it is likely to prevail in demonstrating a
likelihood of confusion. Accordingly, Plaintiff’s motion for a preliminary injunction will be
denied.
A. Direct Confusion
1. Similarity
Generally speaking, the most important Lapp factor used in determining the likelihood of
confusion is the similarity between the marks. Id. at 216 (citing Fisons Horticulture, Inc. v.
Vigoro Indus., 30 F.3d 466, 476 (3d Cir. 1994)). In most cases a side-by-side comparison is not
appropriate. See, e.g., Kos Pharm., Inc., 369 F.3d at 713. Rather, “[t]he proper test is . . .
whether the labels create the same overall impression when viewed separately.” Id. (quoting
Fisons Horticulture, Inc., 30 F.3d at 477). When products are sold next to each other at market,
however, a side-by-side comparison may be appropriate. McNeil Nutritionals, LLC v. Heartland
Sweeteners, LLC, 511 F.3d 350, 359 (3d Cir. 2007) (citing A&H Sportswear, Inc., 237 F.3d at
216). Under either analysis, the Court does not believe that the ProFoot and “P.R.O. Pain Relief
Orthotic” marks are sufficiently similar to warrant issuing a preliminary injunction.
5
In looking at the P.R.O. designation on the packaging to MSD’s Pain Relief Orthotic line
of shoe insoles, the Court is not convinced that the overall impressions created by the ProFoot
mark and the Pain Relief Orthotic mark are the same. Although it would be legal error for the
Court to engage in a “detailed analysis of the differences in the marks rather than focusing on the
overall impression created by them,” Fisons Horticulture, Inc., 30 F.3d at 478, there are several
facts that the Court considers important in reaching its overall impression. First, and perhaps
most importantly in the Court’s mind, on all five Pain Relief Orthotic products the P.R.O.
designation is located immediately next to the words “Pain Relief Orthotic,” thereby indicating
to a consumer that P.R.O. is an acronym. See (Exs. JXT-102, JXT-103, JXT-104, JXT-105,
JXT-106). This is further underscored by the periods immediately following each letter in the
P.R.O. designation. See (id.). Thus, it appears to the Court that, properly framed, the competing
marks are not “ProFoot” versus “P.R.O.”, but rather “ProFoot” versus “P.R.O. Pain Relief
Orthotics” or possibly even “ProFoot” versus “Dr. Scholl’s P.R.O. Pain Relief Orthotics.” See
PB Brands, LLC v. Patel Shah Indian Grocery PB Brands, LLC, 331 F. App’x 975, 980 (3d Cir.
2009) (“The overarching question is whether the marks, ‘viewed in their entirety,’ are
confusingly similar.” (emphasis in original) (quoting Kos Pharm., Inc., 369 F.3d at 714)).
Whether sub-parts of two competing marks are confusingly similar is irrelevant. See Kos
Pharm., Inc., 369 F.3d at 714. The Court, therefore, cannot look at the P.R.O. acronym in
isolation. Moreover, the color, shape, and overall design of the competing marks are
considerably different, which leaves a different overall impression with the Court, as well as
likely consumers.
In addition, if compared side-to-side as these products would be at market, the products
themselves are different in color, shape, and material, all of which is ascertainable by the
consumer as a result of the transparent packaging of each product. See CareFirst of Maryland,
6
Inc. v. First Care, P.C., 434 F.3d 263, 271 (4th Cir. 2006) (“[C]ourts must examine the allegedly
infringing use in the context in which it is seen by the ordinary consumer.”). Similarly, the
packaging (as opposed to only the mark itself) is also sufficiently different to leave distinct
overall impressions in the minds of consumers. All of this plays into how a consumer would
view the use of the P.R.O. acronym in context during its use at market.
Another important distinction is that ProFoot’s trademark consists of its “house brand,”
while MSD’s use of P.R.O. is only one sub-brand of its Dr. Scholl’s “house brand.” “[A]ffixing
a well-known housemark like that of [Dr. Scholl’s] can help diminish the likelihood of
confusion.” A&H Sportswear, Inc., 237 F.3d at 218 (citations omitted). This is because “[u]se
of a strong, well-known mark as a part of a composite name reduces the likelihood that the
remainder of the composite name will create a commercial impression distinct from that mark.”
Id. (collecting cases). During the evidentiary hearing, one of MSD’s executives, James Mackey,
testified that MSD uses the Dr. Scholl’s brand name to market all MSD foot care products, which
is referred to as MSD’s “master brand strategy.” (Tr. 105:1–108:6). The Court finds this
testimony both credible and convincing.
One additional argument is made by ProFoot concerning the visual impression left by the
competing marks. ProFoot contends that the packaging of the Pain Relief Orthotic for “Ball of
Foot” product was specifically designed to accentuate the designation “P.R.O.” and the word
“foot.” ProFoot has not offered any evidence, however, that this was done for the purpose of
confusing consumers; ProFoot relies on mere conjecture. Moreover, the Court does not find this
argument persuasive because all five Pain Relief Orthotic products have the “P.R.O.”
designation followed by progressively larger words contained underneath. Compare (Ex. JXT106) with (Ex. JXT-102, JXT-103, JXT-104, JXT-105); see also (Tr. 153:17–156:11 (discussing
placement of words on the packing)).
7
The closest similarity in the Court’s view between the P.R.O. designation and ProFoot is
auditory; both the P.R.O. acronym and the first syllable in ProFoot are pronounced the same.
But, this alone does not give the Court the overall impression that the Pain Relief Orthotic brand
and ProFoot are from the same source. In A&H Sportswear, Inc., for example, the court found
that “Miraclesuit” and “The Miracle Bra” created different auditory impressions, despite the use
of the same word in each name. See A&H Sportswear, Inc., 237 F.3d at 217. Here, like in A&H
Sportswear, Inc., the two marks have a different number of syllables, the last syllable of each is
different, and ProFoot bleeds two words together while P.R.O. Pain Relief Orthotics is a
combination of several words. Id. These factors all weigh against the two marks sounding
similar. As noted above, P.R.O. is rarely, if ever, heard at market without reference to the Dr.
Scholl’s house brand. This helps to further differentiate the overall impression created by the
sound of the two marks at issue.
In sum, the Court is not left with the overall impression that the marks or products are
related or would likely lead a consumer to the impression that the marks or products are related.
Therefore this factor weighs in favor of MSD.
2. Actual Confusion
ProFoot has also not offered any convincing evidence that consumers have actually been
confused by MSD’s use of the P.R.O. acronym. ProFoot has proffered two exhibits that it claims
show customer confusion. This evidence, however, fails to link any confusion to MSD’s use of
the P.R.O. acronym.
The first piece of evidence proffered by ProFoot is a hand-written letter signed by a
person named Frosty Deyarmin. (Ex. PXT-21). In this letter, the customer notes that he or she
had recently bought a pair of Dr. Scholl’s shoes and that he or she was left unsatisfied by this
purchase. (Id.). The customer also bought a pair of Dr. Scholl’s shoe insoles, which were
8
subject to a money-back guarantee. (Id.). In this letter the customer asks whether this same
money-back guarantee applied to the pair of shoes that the customer purchased or whether it
applies only to the shoe insoles. (Id.). For some unexplained reason, instead of being sent to
MSD, this letter was sent to ProFoot—addressed as “Proof, Inc.” on the envelope in which the
letter was sent. Plaintiff argues that this is evidence that Defendant’s use of the P.R.O. acronym
is causing confusion in the market. This letter is undated, (Tr. 69:18–20), and ProFoot’s witness
was only able to say that the letter was sent at some point in the last six months, (id. 69:22).
Moreover, there is nothing to indicate that the customer had ever seen the Pain Relief Orthotic
brand of Dr. Scholl’s shoe insoles or its use of the P.R.O. acronym. (Tr. 69:23–70:21). Simply
put, this letter may show some sort of customer confusion, but the source of this confusion is
merely speculative and the Court does not believe that it is probative of customer confusion over
the use of the P.R.O. designation by MSD.
The second piece of evidence that Plaintiff claims shows actual confusion in the
marketplace is an email sent on February 21, 2012 from a customer to a ProFoot employee. (Ex.
PXT-22). In this email, the customer complains that version 2.2 of the 2 oz. Miracle, a ProFoot
product, is not as good as the original version. (Id.). After making this complaint, the customer
states: “Dr. Scholl’s has taken over stores and their products don’t compare to the original
miracle. Is the reason you stopped the product because you sold it to Dr Scholl [sic] and they
threw it away to never be seen again[?]” (Id.). This email does not mention whether the
customer has ever seen MSD and Dr. Scholl’s use of the P.R.O. acronym. (Tr. 67:17–68:11).
The customer’s question also underscores the fact that they were aware that a difference existed
between ProFoot and Dr. Scholl’s products. Although the customer questions whether Dr.
Scholl’s has bought ProFoot, this inquiry seems to be based upon the customer’s perception of
Dr. Scholl’s market dominance. (Ex. PXT-22 (Dr. Scholl’s has taken over stores . . . .”)). At the
9
very least, nothing suggests that this inquiry was a result of the customer seeing Dr. Scholl’s use
of the P.R.O. acronym other than the timing of the email.
The Court is not convinced that either of these exhibits shows evidence of actual
confusion occurring in the market. Moreover, MSD has been using the P.R.O. designation for at
least eight months, if not longer. See (Tr. 49:18–24). If actual confusion is in fact occurring,
stronger evidence of this confusion likely would have emerged by this time. “Evidence of only a
small number of instances of actual confusion can be dismissed as inconsequential or de minimis.
For example: Just as one tree does not constitute a forest, an isolated instance of confusion does
not prove probable confusion. To the contrary, the law has long demanded a showing that the
allegedly infringing conduct carries with it a likelihood of confounding an appreciable number of
reasonably prudent purchasers exercising ordinary care.” McNeil Nutritionals, LLC, 511 F.3d at
366 (internal citations and quotations omitted). Plaintiff has offered only two correspondences
allegedly showing actual confusion, and to the extent that these correspondences do show
confusion, there is nothing linking this confusion to MSD’s use of the P.R.O. acronym. Lapp
factors four and six thus weigh in favor of MSD.
3. Intent
When evidence is presented that a defendant intentionally and willfully adopted a mark in
order to promote confusion, this factor weighs strongly in favor of finding a likelihood of
confusion. See Kos Pharm., Inc., 369 F.3d at 721 (quoting Checkpoint Sys. v. Check Point
Software Techs., Inc., 269 F.3d 270, 286 (3d Cir. 2001)). Plaintiff, however, has not presented
any such evidence. Instead, Plaintiff relies on mere conjecture to support this factor.
Plaintiff first argues that MSD’s desire to capture the entire foot-care market is probative
of intent to cause confusion. To the extent that Plaintiff has submitted evidence that shows MSD
sought to, as Plaintiff puts it, “eliminate PROFOOT from the marketplace for foot care devices,”
10
(Pl.’s Br. at 25), the Court gives this evidence little weight. As in any robust industry, directly
competing companies often seek to outperform their rivals and, if possible, eliminate them from
the market. The real question is whether one company seeks to accomplish this goal through
inappropriate means such as improperly trading on another company’s mark.
The first piece of evidence ProFoot proffers in order to establish intent to confuse
consumers is an internal MSD document with a hand-written note in the margin. (Spiro Cert.,
Ex. T). This document shows a picture of a newly-designed draft version of the Pain Relief
Orthotic packaging containing the use of the P.R.O. acronym from February of 2011. (Id.). This
draft version of the packaging used the word “PRO,” without periods placed at the end of each
letter. (Id.). An arrow points from the “PRO Pain Relief Orthotic” portion of the packaging to
the following notes written in the margin: “Jean worried about Professional, vertical treatment,
highlight first letter, periods.” (Id.). According to MSD, “Jean” is Jean Mazet, MSD’s
Consulting Manager for Foot Care, Regulatory Affairs. Ms. Mazet’s job consists of reviewing
proposed product packaging and advertising in order to ensure compliance with applicable FDA
guidelines and other regulations. (Mazet Cert. ¶ 1). According to Ms. Mazet’s sworn
certification, the suggestions listed were meant to insure that consumers would not get the
impression that MSD was promoting its Pain Relief Orthotic brand as a replacement for those
products/services offered by foot-care professionals, such as podiatrists or medical doctors. (Id.
¶ 3). MSD apparently took Ms. Mazet’s recommendation to place periods after each letter
because this change was made from the draft version of the packaging to the final version. Ms.
Mazet claims that this note was not in reference to ProFoot, (Id. ¶ 4), and ProFoot has offered
only conjecture to refute this assertion.
In any event, “a defendant’s mere intent to copy, without more, is not sufficiently
probative of the defendant’s success in causing confusion to weigh such a finding in the
11
plaintiff’s favor; rather, defendant’s intent will indicate a likelihood of confusion only if an intent
to confuse consumers is demonstrated via purposeful manipulation.” A&H Sportswear, Inc., 237
F.3d at 225–26 (citing Versa Prods. Co. v. Bifold Co. (Mfg.), 50 F.3d 189, 205–06 (3d Cir.
1995)). In other words, the intent relevant for this Lapp factor is the intent to confuse the
consumer, not the intent to copy the mark at issue. This note says nothing about the intent to
confuse. If anything, under Plaintiff’s interpretation, it indicates a desire to not confuse
consumers by proposing suggestions to differentiate the mark. Regardless, “copying, absent an
intent to confuse, might do no more than signal to potential consumers that the junior user’s
product is in direct competition with the senior user’s product. Such copying might thus serve a
[positive] communicative function.” Id. at 226 n.16 (citing Conopco, Inc. v. May Dep’t Stores
Co., 46 F.3d 1556, 1565 (Fed. Cir. 1994)).
The next piece of evidence offered by ProFoot of MSD’s alleged intent to confuse
consumers is an email from an MSD employee that refers to ProFoot as “Pro.” See (Spiro Cert.,
Ex. O). This email was sent in May of 2008. The Court does not believe that a single passing
reference to ProFoot as “Pro” in all of MSD’s internal communications is indicative of intent to
cause confusion. In a similar vein, ProFoot’s only fact witness, Daniel Feldman, Executive Vice
President, testified that others in the marketplace refer to ProFoot as “Pro.” (Tr. 97:23–98:9,
99:10–24). Plaintiff therefore argues that MSD must have known that its use of the P.R.O.
acronym was going to cause confusion. This testimony, however, is self-serving and Plaintiff
offered no other evidence to support this contention. Further, as noted above, ProFoot does not
argue that it has a trademark in the name “Pro.” Therefore, the Court does not consider this
argument compelling.
ProFoot has offered no other evidence indicative of intent to confuse on behalf of MSD.
Mr. Feldman testified at the evidentiary hearing that it was his belief that Dr. Scholl’s launched
12
the Pain Relief Orthotic line of products in 2006 with the intent to, at some later time, shorten
this to P.R.O. for the purpose of trading off of ProFoot’s brand name. (Tr. 91:3–92:5). This
belief, however, has no evidence to support it. (Tr. 92:1–5 (admitting he has no evidentiary
support)).
“[T]he defendant’s intent may be discovered through such inquiries as whether the
defendant was aware of the senior user’s mark when it adopted its own mark, and whether the
defendant considered that its adoption of the mark might result in confusion.” A&H Sportswear,
Inc., 237 F.3d at 232 (citations omitted). At the same time, however, “mere carelessness, as
opposed to deliberate intent to confuse[,] . . . does not shed light on this inquiry.” Id. at 232–33.
Therefore, because ProFoot’s arguments are based almost entirely on conjecture, the Court does
not believe that ProFoot has demonstrated that MSD had the intent to cause confusion by using
the P.R.O. acronym. This Lapp factor therefore weighs in favor of MSD.
4. Strength of ProFoot’s Mark
In looking at a direct confusion claim the stronger a plaintiff’s mark is, the more
protection that mark should receive. See Kos Pharm., Inc., 369 F.3d 715. Because a strong mark
has greater recognition, a similar mark is more likely to cause confusion. Id. (quoting A&H
Sportswear, Inc., 237 F.3d at 222). The strength of a mark is measured by two prongs: (1) the
distinctiveness or conceptual strength of the mark; and (2) the commercial strength or
marketplace recognition of the mark. Fisons Horticulture, Inc., 30 F.3d at 479.
In determining the conceptual strength of a mark, courts have devised four categories: (1)
generic; (2) descriptive; (3) suggestive; and (4) arbitrary or fanciful. See Two Pesos, Inc. v. Taco
Cabana, Inc., 505 U.S. 763, 768 (1992).
Arbitrary or fanciful marks use terms that neither describe nor suggest anything
about the product; they bear no logical or suggestive relation to the actual
characteristics of the goods. Suggestive marks require consumer imagination,
13
thought, or perception to determine what the product is. Descriptive terms
forthwith convey an immediate idea of the ingredients, qualities or characteristics
of the goods. Generic marks are those that function as the common descriptive
name of a product class.
A&H Sportswear, Inc., 237 F.3d at 222 (internal citations and quotations omitted). Descriptive,
suggestive and arbitrary marks receive trademark protection, while generic marks do not. Id.
(citing A.J. Canfield Co. v. Honickman, 808 F.2d 291, 297, 305 (3d Cir. 1986)). This
classification system, however, is not the only measure of conceptual strength of a mark. Id.
Although suggestive and arbitrary marks are generally considered “strong,” marks falling within
these categories may still be considered “weak.” Id. This is especially true when the mark is
used in connection with a number of different products, is a term or phrase commonly used by
other companies, or when the term is “self-laudatory.” Id. (citations omitted).
In this case, the mark “ProFoot” is neither conceptually strong nor conceptually weak.
Plaintiff’s mark is very similar to the mark analyzed by the United States Court of Appeals for
the Third Circuit in A&H Sportswear, Inc. There, the court held that the mark “Miraclesuit”
was, at best, a suggestive mark. Id. at 223. The court further reasoned that the use of the term
“miracle” in other markets had a weakening effect on the mark. In this case, the term “pro”—
often used as shorthand for “professional,” as it is here—is a run-of-the-mill word similarly
weakened by its pervasive use by others in commerce. Similarly, the word “pro” is often used in
a self-laudatory sense. Therefore, the Court concludes that Plaintiff’s mark is conceptually
neutral—i.e., it is neither particularly strong nor particularly weak.
After reviewing the evidence presented, the Court also believes that the commercial
strength of Plaintiff’s mark is, at best, neutral. This prong of the second Lapp factor looks to
factual evidence of marketplace recognition. See, e.g., Pa Bus. Bank. v. Biz Bank Corp., 330 F.
Supp. 2d 511, 520 (E.D. Pa. 2004) (citing A&H Sportswear, Inc., 237 F.3d at 221).
14
There are at least four pieces of evidence that support a finding that Plaintiff’s mark is
commercially strong. First, ProFoot is the second largest competitor in this market. Second,
ProFoot has spent large sums of money on advertising. “Although evidence of money spent [on
marketing] does not automatically translate into consumer recognition, it is clearly relevant” to
the commercial strength of a plaintiff’s mark. A&H Sportswear, Inc., 237 F.3d at 224. Third,
ProFoot has made continuous use of its mark in commerce since 1995, although in different
iterations. Finally, ProFoot offered evidence of a non-exclusive licensing agreement with
another company. See Pa Bus. Bank. v. Biz Bank Corp., 330 F. Supp. 2d 511, 520 (E.D. Pa.
2004) (weighing both the extended length of use of a mark and a licensing agreement with
another commercial entity in favor of commercial strength). Although all of these factors weigh
in favor of finding a commercially strong mark, they must be balanced against the evidence
tending to show the commercial weakness of Plaintiff’s mark. Defendant’s expert, Dr. Alex
Simonson, conducted a “fame survey” that tested, among other things, the name recognition of
ProFoot. Dr. Simonson’s report concluded that only 6.2% of the 406 qualified respondents knew
of the brand name ProFoot. (Simonson Cert., Ex. A at 8–16).
Balancing all of this evidence together, the Court does not believe that the strength of
Plaintiff’s mark in this case is particularly probative of the question of whether consumers are
likely to be confused by MSD’s use of the P.R.O. acronym.
5. Care and Attention Expected of Consumers
The parties next dispute the amount of care consumers use in purchasing orthotic shoe
insoles. After reviewing the evidence, the Court does not find this factor particularly helpful to
its overall analysis. There are two competing concerns that, in the Court’s view, weigh equally
against each other in analyzing this Lapp factor: the inexpensive nature of orthotic shoe insoles
and the purpose of this type of shoe insole, which is to relieve or prevent pain.
15
“Inexpensive goods require consumers to exercise less care in their selection than
expensive ones.” Versa Prods. Co., 50 F.3d at 204. In addition to cost, other relevant
considerations can include whether “the sales process is as quick as a trip to the check-out
counter,” whether consultation with a professional is necessary, and whether consumers often
buy these products as an “impulse purchase.” Sabinsa Corp. v. Creative Compounds, LLC, 609
F.3d 175, 187 (3d Cir. 2010). Here, the price of the shoe insoles is roughly between fourteen to
sixteen dollars. (Tr. 121:23–122:4). This is affordable for most consumers and no special
medical knowledge or access is needed to purchase these products.
At the same time, however, the purpose of orthotic shoe insoles is to relieve or prevent
pain. Many consumers, therefore, are likely to consider this an important purchase. “The more
important the use of the product, the more care that must be exercised in its selection.” Versa
Prods. Co. v. Bifold Co. (Mfg.), 50 F.3d 189, 205–06 (3d Cir. 1995). “[H]eightened awareness
of health . . . raises the standard of care which the reasonable purchaser of the parties’ products
would exercise.” McNeil Nutritionals, LLC, 511 F.3d at 364; see also Morgenstern Chem. Co. v.
G.D. Searle & Co., 253 F.2d 390, 393 (3d Cir. 1958) (noting the importance of avoiding
mistakes and confusion in the market for medical products); Kos Pharm., Inc., 369 F.3d at 715–
17 (discussing same). Here, Dr. Scholl’s Pain Relief Orthotics foot care products are over-thecounter medical devices that are clinically proven to relieve specific medical symptoms in
accordance with FDA guidelines. (Howard Decl. ¶ 14).
Weighing these two considerations against each other, the Court believes that this factor
slightly favors ProFoot. This Lapp factor, however, is not particularly probative in this case.
6. Remaining Lapp Factors
In analyzing likelihood of confusion, “the court need not apply each and every factor.”
A&H Sportswear, Inc., 237 F.3d at 214. This is especially true when products directly compete
16
against one another. Id. The Court does not consider the remaining Lapp factors at all relevant
to its determination. The parties do not dispute that MSD’s line of Dr. Scholl’s Pain Relief
Orthotic shoe insoles directly compete with corresponding ProFoot products. (Tr. 46:23–25).
Because these products directly compete, it should come as no surprise that they are marketed to
roughly the same (though not identical) target customer base, are marketed through similar
(though not identical) channels,2 have similar functions, etc.
7. Summary
“[T]he Lapp test is a qualitative inquiry.” A&H Sportswear, Inc., 237 F.3d at 215. This
means that “different factors may properly be accorded different weights,” including no weight
at all, “depending on the particular factual setting.” Id. This case must be viewed in light of the
fact that MSD has been selling its Dr. Scholl’s Pain Relief Orthotic line of shoe insoles since
2006 and the fact that ProFoot does not have a trademark for the word “pro.” Although ProFoot
has in the past produced other “pro-”products, it is presumed that Plaintiff has since abandoned
any trademark ownership interest that may have existed in these products. See 15 U.S.C. § 1127.
Despite not formally making a “family of marks” argument, it appears to the Court that Plaintiff
is attempting to indirectly do just that.
To be effective, the “family of marks” argument must rest in the ultimate analysis
on proof by plaintiff that the designation constituting the “surname” of the family
is in fact recognized by the public as a trademark in and of itself. Usually, this
requires some proof that the “family surname” has been so extensively advertised
that buyers would be likely to think that defendant’s product originates with
plaintiff.
J. Thomas McCarthy, MCCARTHY ON TRADEMARKS AND UNFAIR COMPETITION, § 23:61 (4th ed.
2008). Despite ProFoot’s Executive Vice President’s testimony that “for 25 years, [ProFoot has]
2
Although the Court does not consider this factor relevant in this case, it nevertheless notes that this factor likely
weighs in favor of MSD. See PB Brands, LLC, 331 F. App’x at 983 (concluding that district court did not abuse its
discretion in finding that the parties marketed through different channels when one party marketed through
television, radio, newspapers, magazines, trade publications, flyers, brochures, and calendars, while the other party
marketed only through flyers in the local community).
17
been establishing [it]self as . . . the PRO brand,” (Tr. 51:4–5), it has not, at least as far as the laws
of trademark are concerned.
In this case, the most important Lapp factors in the Court’s view are the similarity of the
mark, the intent of MSD in using the P.R.O. acronym, evidence of actual confusion, and the
length of time a mark has been used without confusion. All four of these factors weigh in favor
of denying Plaintiff’s motion. The remaining factors are not particularly probative of likely
consumer confusion or are otherwise neutral. Therefore, MSD’s use of the P.R.O. acronym is
not likely to cause confusion and Plaintiff is unlikely to succeed on the merits of its direct
confusion claim.
B. Reverse Confusion
In the context of a reverse confusion claim many of the Lapp factors are analyzed in the
same manner as in a direct confusion claim. A&H Sportswear, Inc., 237 F.3d at 229. Some
differences may exist, however, because reverse and direct confusion claims seek redress for
different types of harm. As explained above, reverse confusion occurs when a junior user
utilizes a senior user’s mark and this causes the senior user to somehow become connected to the
junior user in the minds of consumers. Id. (citations omitted). The Lapp factors should therefore
be tailored toward redressing this situation when analyzed under a reverse confusion claim.
There are two differences between direct and reverse confusion claims recognized by the Third
Circuit that are relevant to this case. The first analytic distinction involves the similarity of the
marks and the second concerns the strength of the parties’ marks.
The first Lapp factor—i.e., the similarity of the marks—is generally “analyzed the same
way in direct and reverse confusion claims; the court looks to sight, sound, and meaning, and
compares whether these elements combine to create a general commercial impression that is the
same for the two marks.” Id. (citing Fisons Horticulture, Inc., 30 F.3d at 478–79). “[A] district
18
court would not need to examine these in a different manner than it would in a direct confusion
claim.” Id. There is one difference that is recognized in the Third Circuit relevant to this case,
however, which concerns the use of house marks. Although the use of a house mark usually
lessens the risk of consumer confusion, “there is also the possibility that the mark will aggravate,
rather than mitigate, reverse confusion, by reinforcing the association of the word [‘pro’]
exclusively with [MSD and Dr. Scholl’s].” Id. at 230 (citing Sands, Taylor & Wood Co. v.
Quaker Oats Co., 978 F.2d 947, 960 (7th Cir. 1992); Americana Trading Inc. v. Russ Berrie &
Co., 966 F.2d 1284, 1288 (9th Cir. 1992)). But, this does not necessarily occur in every case.
See id. (“Of course, we do not mean to suggest that this actually occurred in this particular case .
. . .”). No evidence was presented in this case that consumers now link the word “pro” with Dr.
Scholl’s and MSD other than Dr. Scholl’s new marketing campaign urging consumers to “go
pro.” See, e.g., (Tr. 57:17–58:6). Absent evidence that this marketing has actually had the effect
of reinforcing the association of “pro” exclusively with Dr. Scholl’s, the Court does not consider
this marketing campaign on its own accord to be very probative in this case. See A&H
Sportswear, Inc., 237 F.3d at 224 (“[E]vidence of money spent [on marketing] does not
automatically translate into consumer recognition . . . .”). Therefore, for the reasons discussed
above, see supra Part II.A.1, the Court believes that the first Lapp factor weighs in favor of MSD
on Plaintiff’s reverse confusion claim.
The next difference between direct and reverse confusion claims relevant to this case
concerns the strength of the marks at issue. Unlike a direct confusion claim, which focuses
almost exclusively on the strength of the plaintiff’s mark, in a reverse confusion claim the focus
of a district court’s analysis should be on the strength of the junior user’s mark. See A&H
Sportswear, Inc., 237 F.3d at 230–31. “[I]n a reverse confusion claim, a plaintiff with a
commercially weak mark is more likely to prevail than a plaintiff with a stronger mark, and this
19
is particularly true when the plaintiff’s weaker mark is pitted against a defendant with a far
stronger mark.” Id. at 231. This is because “it is the strength of the larger, junior user’s mark
which results in reverse confusion.” Commerce Nat'l Ins. Servs., Inc., 214 F.3d at 444. As
discussed above, in the direct confusion context this Lapp factor was neutral and not very
probative. In the reverse confusion context, however, this factor undoubtedly favors ProFoot.
The Dr. Scholl’s mark is conceptually strong because this name is arbitrary and fanciful and it is,
by Defendant’s own measure, commercially strong as well. See (Tr. 118:24 (“[A]lmost everyone
[has] heard of it . . . .”); 119:13–14 (“In general, we spend an enormous amount of money on
advertising and consumer promotions, in the tens of millions of dollars year after year.”)); see
also A&H Sportswear, Inc., 237 F.3d at 231 (“[I]n a reverse confusion claim, a court should
analyze the ‘commercial strength’ factor in terms of (1) the commercial strength of the junior
user as compared to the senior user; and (2) any advertising or marketing campaign by the junior
user that has resulted in a saturation in the public awareness of the junior user’s mark.” (citing
Fisons Horticulture, Inc., 30 F.3d at 474, 479)).
With the exception of these two differences, the analysis in the reverse confusion context
for determining whether there is a likelihood of confusion is the same as that used for Plaintiff’s
direct confusion claim discussed above. In the reverse confusion context at least one of the Lapp
factors favors ProFoot, but the Court does not believe that this alone warrants the conclusion that
Plaintiff is likely to succeed in proving the merits of this claim. The dissimilarity of the marks,
the lack of a deliberate intent to confuse by MSD in adopting the P.R.O. acronym, and the lack
of evidence of actual confusion (even after eight months have passed since MSD started using
the P.R.O. acronym) all still weigh in favor of MSD in the reverse confusion context. The Court,
therefore, does not believe that Plaintiff is likely to succeed on the merits in proving its reverse
confusion claim.
20
C. Unfair Competition
Plaintiff also seeks a preliminary injunction based upon his state-law claims for unfair
competition. “There is no distinct cause of action for unfair competition. It is a general rubric
which subsumes various other causes of action.” C.R. Bard, Inc. v. Wordtronics Corp., 561 A.2d
694, 696 (N.J. Super. Ct. 1989). In order to succeed on this claim, Plaintiff still will have to
prove a likelihood of confusion. See, e.g., SK&F, Co. v. Premo Pharm. Labs., Inc., 625 F.2d
1055, 1066 (3d Cir. 1980) (“[E]xcept for the interstate commerce requirement, the elements of
the unfair competition torts proscribed by New Jersey law and by section 43(a) of the Lanham
Act are the same . . . .”). Therefore, the same analysis above also applies with full force to
Plaintiff’s unfair competition claims.
IV.
IRREPARABLE HARM
The next prong of a preliminary injunction analysis is whether the plaintiff will suffer
irreparable harm as a result of the defendant’s actions if an injunction is denied. See Kos
Pharm., Inc., 369 F.3d at 708 (citing Allegheny Energy, Inc., 171 F.3d at 158). The Court has
determined that ProFoot has not satisfied this prong.
In attempting to establish irreparable harm ProFoot argues that “[o]nce the likelihood of
confusion caused by trademark infringement has been established,” irreparable harm is also
established as a matter of law. Kos Pharm., Inc., 369 F.3d at 726 (citing Pappan Enters., Inc. v.
Hardee’s Food Sys., Inc., 143 F.3d 800, 805 (3d Cir. 1998)). By contrast, MSD argues that—
even assuming Plaintiff has established the likelihood of confusion—the Third Circuit precedent
establishing a presumption of irreparable harm has since been superseded by the Supreme Court
of the United State’s decision in eBay, Inc. v. MercExchange, LLC, 547 U.S. 388 (2006). MSD
then argues that Plaintiff has not submitted evidence of actual irreparable harm, and because
21
ProFoot can no longer rely on a presumption to establish this prong, an injunction should be
denied.
In MercExchange, the Court held that the traditional four-factor test for issuing a
preliminary injunction should apply to patent cases and that granting an injunction based upon a
categorical rule should be avoided. Id. at 393–94. Some federal courts throughout this country
have expanded this reasoning into the context of trademark infringement. See, e.g., New York
City Triathlon, LLC v. NYC Triathlon Club, Inc., 704 F. Supp. 2d 305, 342–43 (S.D.N.Y. 2010).
And although courts in this circuit have continued to adhere to the old rule permitting a
presumption of irreparable injury once likelihood of confusion is established,3 it also appears that
no court in this circuit has specifically addressed the issue now presented. See Schering-Plough
Healthcare Prods., Inc. v. Neutrogena Corp., No. 09-642, 2011 U.S. Dist. LEXIS 61165, at *5
(D. Del. June 8, 2011) (citations omitted) (noting that “[t]here is no clear indication that this
presumption still applies in the wake of [MercExchange]” and explicitly avoiding answering this
question). Because the Court has already determined that Plaintiff is unlikely to succeed on the
merits, this unsettled question of law need not be answered by the Court.
There is another reason that the Court believes that Plaintiff will not suffer irreparable
harm. ProFoot became aware of MSD’s intent to use the P.R.O. acronym in its product branding
at some time in the summer of 2011. See (Tr. 47:18–48:7). It is not clear to the Court that
ProFoot should have acted at this point to stop MSD’s use of the P.R.O. acronym because there
3
See Coach, Inc. v. Fashion Paradise, LLC, No. 10-4888, 2012 U.S. Dist. LEXIS 7429, at *25 (D.N.J. Jan. 20,
2012) (citation omitted) (adhering to old rule without discussion); Mt. Nittany Med. Ctr. v. Nittany Urgent Care,
P.C., No. 11-622, 2011 U.S. Dist. LEXIS 134585, at *8 (M.D. Pa. Nov. 22, 2011) (citations omitted) (same);
Sabinsa Corp. v. Creative Compounds, LLC, No. 04-4239, 2011 U.S. Dist. LEXIS 82001, at *18–20 (D.N.J. July
27, 2011) (same); World Entm’t, Inc. v. Brown, No. 09-5365, 2011 U.S. Dist. LEXIS 55182, at *18–21 (E.D. Pa.
May 20, 2011) (briefly discussing issue but without reference to MercExchange); Alliance Bank v. New Century
Bank, 742 F. Supp. 2d 532, 565–66 (E.D. Pa. 2010) (applying old rule but also citing to MercExchange while noting
that equitable considerations in the case also warranted the issuance of a preliminary injunction). But see Louis
Vuitton Malletier, S.A. v. Mosseri, No. 07-2620, 2009 U.S. Dist. LEXIS 100851, at *14–17 (D.N.J. Oct. 28, 2009)
(citing MercExchange and relying on equitable considerations rather than a presumption in issuing an injunction).
22
is testimony indicating that the NACS marketplace (where Plaintiff first became aware of MSD’s
possible use of the P.R.O. designation) is a sounding board for possible ideas that companies
may or may not bring to market. (Id. 48:21–49:17). By early September 2011 at the latest,
however, ProFoot knew that MSD had started using the P.R.O. acronym in the market. (Id.
49:18–24). Plaintiff did not file the present suit until December 5, 2011. (Compl.) [1]. Plaintiff
also did not send MSD a cease-and-desist letter prior to filing its Complaint in this case. (Tr.
65:23–66:3).
“Where a Plaintiff delays in seeking preliminary injunctive relief, such delay is evidence
that speedy relief is not needed.” EMSL Analytical, Inc. v. Testamerica Analytical Testing Corp.,
No. 05-5259, 2006 U.S. Dist. LEXIS, at *38–39 (D.N.J. Apr. 4, 2006) (collecting cases). An
unjustified delay—in this case at least three months—“knocks the bottom out of any claim of
immediate and irreparable harm.” Pharmacia Corp. v. Alcon Labs., Inc., 201 F. Supp. 2d 335,
383–84 (D.N.J. 2002) (collecting cases).4 Because of this unjustified delay and because Plaintiff
has not otherwise shown a likelihood of success on the merits, ProFoot has not established that it
is being irreparably harmed by MSD’s use of the P.R.O. acronym.
V.
GREATER HARM TO MSD
The third prong of a preliminary injunction analysis asks whether greater harm will inure
to the defendant if an injunction is granted as compared to the harm suffered by the Plaintiff if an
injunction is not granted. See Kos Pharm., Inc., 369 F.3d at 708 (citing Allegheny Energy, Inc.,
171 F.3d at 158). ProFoot argues that any harm suffered by MSD is self-inflicted because MSD
4
Moreover, when Plaintiff filed its Complaint, it was not accompanied with a motion for a preliminary injunction.
Rather, Plaintiff concurrently filed with its Complaint a motion for expedited discovery in aid of a future motion for
a preliminary injunction. [1-2]. Although this may be entirely appropriate in many cases, in the context of this
case—a trademark infringement case between directly competing goods—it seems odd in light of the Third Circuit’s
statement that a court “need rarely look beyond the mark itself” in determining whether a likelihood of confusion
exists. Lapp, 721 F.2d at 462. Although the Court is aware that this statement “may be an exercise in unjustified
optimism,” A&H Sportswear, Inc., 237 F.3d at 212, the need for expedited discovery nevertheless undercuts
Plaintiff’s argument that the similarity between the use of the P.R.O. acronym and ProFoot’s mark is self-evident.
23
failed to do the appropriate due-diligence to determine whether its use of the P.R.O. acronym
would likely cause consumer confusion. Therefore, ProFoot posits, MSD should not be able to
argue that it would suffer harm as a result of an injunction. This argument relies on the
assumption that ProFoot has established a likelihood of consumer confusion, but as discussed
above, ProFoot has not made this showing. For this reason, Plaintiff’s argument must be rejected
by the Court.
In addition, Defendant has submitted evidence that it will suffer a significant monetary
harm if an injunction was issued. Plaintiff seeks an order from the Court mandating, among
other things, that MSD cover up the use of the P.R.O. acronym on its packaging by placing a
sticker over it. This would undoubtedly cost a considerable amount of money. See generally
(Tr. 138:14–139:22 (explaining process of placing stickers on products)). Although the Court is
not convinced that this harm is necessarily significant in the larger context of this case, it is harm
nevertheless. Therefore, Plaintiff has failed to satisfy the third prong of a preliminary injunction
analysis.
VI.
PUBLIC INTEREST
The final prong of a preliminary injunction analysis asks whether the public interest
favors the issuance of an injunction. See Kos Pharm., Inc., 369 F.3d at 708 (citing Allegheny
Energy, Inc., 171 F.3d at 158). ProFoot argues that the public interest at stake in this case is
synonymous with the right of the public not to be deceived or confused. See Opticians Ass’n of
Am. v. Indep. Opticians of Am., 920 F.2d 187 (3d Cir. 1990). Again, however, this argument
relies on the assumption that Plaintiff has proven a likelihood of consumer confusion. As
explained above, Plaintiff has not made such a showing. Therefore, ProFoot’s argument must be
rejected. Thus, Plaintiff has failed to satisfy this fourth prong of a preliminary injunction
analysis as well.
24
VII.
CONCLUSION
For the reasons stated above, it is on this 14th day of June, 2012,
ORDERED that Plaintiff’s Motion for a Preliminary Injunction [42] is DENIED.
/s/ Anne E. Thompson
ANNE E. THOMPSON, U.S.D.J.
25
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?